Access Pharmaceuticals, Inc. - Price Analysis Snapshot

This Report features up to a ten-year record of the equity Price history for Access Pharmaceuticals, Inc.. Tabular results include the High, Low and Closing price for the quarter. There is also a calculation of percentage change in price for both Quarterly and Annual periods. Price values are adjusted for stock splits and dividends.

Access Pharmaceuticals, Inc.. The Group's principal activity is to develop drug delivery systems and advanced polymer technology for application in cancer treatment, dermatology and treatment of oral diseases. It is in the development stage. The Group has proprietary patents and rights to seven drug delivery technology platforms: synthetic polymer targeted delivery, vitamin mediated targeted delivery (including oral), bioerodible hydrogel technology, nanoparticles and nanoparticle networks, Residerm (R) topical delivery, carbohydrate targeting technology and agents for the prevention and treatment of viral disease, including HIV. The products Residerm (R) A gel - Zindaclin (TM), Aphthasol (R) and Aptheal (R) are being marketed currently. On 25-February-2009, the Group acquired MacroChem Corporation.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report